ストックスクリーナーアプリを入手
47.08
1.30%
-0.62
前日終値:
$47.70
開ける：
$47.59
24時間の取引高:
310.29K
Relative Volume:
0.79
時価総額：
$990.84M
収益：
$1.77M
当期純損益:
$-123.74M
株価収益率:
-5.1341
EPS:
-9.17
ネットキャッシュフロー:
$-95.21M
1週間 パフォーマンス:
+2.48%
1か月 パフォーマンス:
-9.27%
6か月 パフォーマンス:
-48.13%
1年 パフォーマンス:
-13.61%
1日の値動き範囲:
$46.64
$47.76
1週間の範囲:
$44.25
$49.97
52週間の値動き範囲:
$26.70
$91.83
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
名前
Praxis Precision Medicines Inc
セクター
電話
617-300-8460
住所
99 HIGH STREET, 30TH FLOOR, BOSTON
PRAX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
47.08 | 1.00B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-02 | 再開されました | Oppenheimer | Outperform |
| 2025-05-07 | 開始されました | Chardan Capital Markets | Buy |
| 2025-03-03 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2024-08-05 | 開始されました | Oppenheimer | Outperform |
| 2024-06-24 | 開始されました | Needham | Buy |
| 2024-06-18 | 開始されました | Guggenheim | Buy |
| 2024-05-01 | 開始されました | Robert W. Baird | Outperform |
| 2023-09-19 | 開始されました | Truist | Buy |
| 2022-06-06 | ダウングレード | Wedbush | Outperform → Neutral |
| 2021-12-16 | 開始されました | H.C. Wainwright | Buy |
| 2021-08-26 | 開始されました | BofA Securities | Buy |
| 2021-04-26 | 開始されました | William Blair | Outperform |
| 2020-11-11 | 開始されました | Wedbush | Outperform |
| 2020-11-10 | 開始されました | Cowen | Outperform |
| 2020-11-10 | 開始されました | Evercore ISI | Outperform |
| 2020-11-10 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Praxis Precision Medicines Inc (PRAX) 最新ニュース
How Praxis Precision Medicines Inc. stock performs during market volatility2025 Year in Review & Low Risk High Reward Trade Ideas - Newser
Advanced analytics toolkit walkthrough for Praxis Precision Medicines Inc.Market Activity Recap & Verified Swing Trading Watchlists - Newser
Can Praxis Precision Medicines Inc. rally from current levelsJuly 2025 Institutional & Accurate Technical Buy Alerts - Newser
Why Praxis Precision Medicines Inc. stock attracts strong analyst attentionNew Guidance & Low Risk Entry Point Tips - Newser
Is Praxis Precision Medicines Inc. stock reversal real or fake2025 Bull vs Bear & High Return Trade Opportunity Guides - Newser
Did Praxis Precision Medicines, Inc. (PRAX) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire
Reversal indicators forming on Praxis Precision Medicines Inc. stock2025 Price Targets & Low Risk Growth Stock Ideas - Newser
Bronstein, Gewirtz & Grossman, LLC Encourages Praxis Precision Medicines, Inc. (PRAX) Investors to Inquire about Securities Investigation - ACCESS Newswire
What indicators show strength in Praxis Precision Medicines Inc.Trade Entry Summary & Daily Growth Stock Investment Tips - Newser
Lost Money on Praxis Precision Medicines, Inc. (PRAX)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Praxis Precision Medicines, Inc. (PRAX) And Encourages Investors to Reach Out - ACCESS Newswire
Praxis Precision Medicines shares fall 1.89% intraday after Schall Law Firm investigates claims of false statements. - AInvest
Levi & Korsinsky Investigates Possible Securities Fraud by Praxis Precision Medicines, Inc. (PRAX) - ACCESS Newswire
PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. Fraud Investigation with the Schall Law Firm - Barchart.com
Will Praxis Precision Medicines Inc. bounce back from current supportGap Up & Safe Capital Allocation Plans - Newser
Does Praxis Precision Medicines Inc. stock pay reliable dividends2025 Buyback Activity & Precise Buy Zone Tips - Newser
Levi & Korsinsky Investigating Whether Praxis Precision Medicines, Inc. (PRAX) Misled InvestorsSecurities Law Violations Possible - ACCESS Newswire
What are the future prospects of Praxis Precision Medicines Inc.Volume Surge With Low Float - thegnnews.com
Will Praxis Precision Medicines Inc. see short term momentumRisk-Managed Trade Alerts for Consistency - Newser
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Praxis Precision Medicines, Inc. (PRAX) - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc.PRAX - PR Newswire
Piper Sandler reiterates Overweight rating on Praxis Precision Medicines stock - Investing.com Nigeria
Chardan Capital Brokers Lower Earnings Estimates for PRAX - Defense World
ATTENTION PRAX Shareholders: Lost Money on Praxis Precision Medicines, Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Praxis Precision Medicines (PRAX) to Release Quarterly Earnings on Tuesday - Defense World
Praxis Precision Medicines Q2 results disappoint, stock falls 5.55% - AInvest
Is Praxis Precision Medicines Inc. meeting your algorithmic filter criteriaReal Market Tracker with Price Action Tools - Newser
What is HC Wainwright’s Forecast for PRAX Q3 Earnings? - Defense World
HC Wainwright Reaffirms Buy Rating for Praxis Precision Medicines (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines’ Positive Earnings Call Highlights Vormatrigine Success - MSN
Praxis Precision Medicines: Marcio Firm's Insights - AInvest
What is Wedbush’s Forecast for PRAX Q3 Earnings? - Defense World
FY2029 Earnings Forecast for PRAX Issued By HC Wainwright - Defense World
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Praxis Precision Medicines Grants 3,875 Restricted Stock Units to Strategic New Hires - Stock Titan
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Q2 2025 Earnings Call Transcript - Insider Monkey
Will Praxis Precision Medicines Inc. stock split in the near futureDaily Pattern Analysis with Return Forecast - Newser
Praxis Precision Medicines Advances Epilepsy Treatment with Promising Study Results and Strong Financial Positioning - AInvest
Praxis Precision Medicines: A Dual-Platform Innovator Capturing the Future of Precision Neurology - AInvest
Praxis Precision Medicines to Participate in Upcoming Fireside C - GuruFocus
Praxis Precision Medicines to Participate in Upcoming Fireside Chat - GlobeNewswire
Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswire
Praxis Precision Medicines stock holds Buy rating at Truist on seizure reduction data - Investing.com India
Praxis Precision Medicines stock holds Buy rating at Truist on seizure reduction data By Investing.com - Investing.com South Africa
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $33 to $155 - 富途牛牛
Praxis Precision Medicines First Half 2025 Earnings: US$6.60 loss per share (vs US$4.58 loss in 1H 2024) - Yahoo Finance
Praxis’ vormatrigine eliminates seizures in 22% of patients in Phase II trial - Yahoo Finance
Praxis Precision Medicines Inc (PRAX) Q2 2025 Earnings Call Highlights: Vormatrigine Shows ... - Yahoo Finance
Praxis Precision Medicines Inc (PRAX) Q2 2025 Earnings Call Highlights: Vormatrigine Shows ... By GuruFocus - Investing.com Canada
Praxis Precision Medicines Reports Promising Study Results - TipRanks
Decoding Praxis Precision Medicines Inc (PRAX): A Strategic SWOT Insight - GuruFocus
Praxis Precision Medicines Inc (PRAX) 財務データ
収益
当期純利益
現金流量
EPS
Praxis Precision Medicines Inc (PRAX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 14 '24 |
Sale |
80.20 |
8,239 |
660,827 |
10,301 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Option Exercise |
56.94 |
4,374 |
249,056 |
10,801 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Sale |
81.78 |
5,188 |
424,318 |
5,613 |
0.41%
0.88%
大文字化:
|
ボリューム (24 時間):